Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: MASLD, particularly in those with simple steatosis
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The p.I148M genotype was not associated with altered levels of microRNAs. [CONCLUSION] Serum microRNAs, in particular miR-4651, may serve as additional biomarkers in patients with steatotic liver disease.
[BACKGROUND AND AIMS] Metabolic dysfunction-associated steatotic liver disease (MASLD) affects >30% of adults and is becoming one of the leading causes of hepatocellular carcinoma (HCC).
APA
Kirchmeyer M, Gaigneaux A, et al. (2026). Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease.. Gastro hep advances, 5(2), 100839. https://doi.org/10.1016/j.gastha.2025.100839
MLA
Kirchmeyer M, et al.. "Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease.." Gastro hep advances, vol. 5, no. 2, 2026, pp. 100839.
PMID
41487453 ↗
Abstract 한글 요약
[BACKGROUND AND AIMS] Metabolic dysfunction-associated steatotic liver disease (MASLD) affects >30% of adults and is becoming one of the leading causes of hepatocellular carcinoma (HCC). Reliable biomarkers are needed for the early diagnosis of HCC and detection of chronic liver diseases, like MASLD. Here we assessed the biomarker potential of circulating microRNAs in a cohort of patients genotyped for the risk allele of (), associated with increased susceptibility to chronic liver diseases.
[METHODS] The cohort comprised 70 MASLD patients (40 with simple steatosis, 9 with metabolic dysfunction-associated steatohepatitis (MASH), 21 with cirrhosis), 47 HCC patients (32 with cirrhosis), and 14 healthy controls. Serum levels of miR-122-5p, miR-146a-5p, miR-146b-5p, miR-21-5p, miR-335-5p, miR-433-3p, miR-4530, miR-4651, miR-526a2, and miR-873-5p were quantified using custom qPCR plates. Their suitability for prediction of MASLD (steatosis/MASH/cirrhosis) or HCC was assessed by receiver operating characteristic curve analyses.
[RESULTS] MiR-4651 and miR-21-5p were significantly reduced in sera from patients with MASLD, particularly in those with simple steatosis. Both microRNAs effectively distinguished MASLD patients with simple steatosis from healthy controls (area under the curve: 0.95 and 0.89, respectively). Moreover, miR-4651 emerged as the best predictor for differentiating "complicated" MASLD (i.e., MASH or cirrhosis) from simple steatosis; the predictive values could be increased by including additional parameters into the models (Fibroscan, thrombocytes, cytokines, or other miRNAs). miR-335-5p showed strong ability to differentiate HCC from healthy individuals (area under the curve: 0.86). The p.I148M genotype was not associated with altered levels of microRNAs.
[CONCLUSION] Serum microRNAs, in particular miR-4651, may serve as additional biomarkers in patients with steatotic liver disease.
[METHODS] The cohort comprised 70 MASLD patients (40 with simple steatosis, 9 with metabolic dysfunction-associated steatohepatitis (MASH), 21 with cirrhosis), 47 HCC patients (32 with cirrhosis), and 14 healthy controls. Serum levels of miR-122-5p, miR-146a-5p, miR-146b-5p, miR-21-5p, miR-335-5p, miR-433-3p, miR-4530, miR-4651, miR-526a2, and miR-873-5p were quantified using custom qPCR plates. Their suitability for prediction of MASLD (steatosis/MASH/cirrhosis) or HCC was assessed by receiver operating characteristic curve analyses.
[RESULTS] MiR-4651 and miR-21-5p were significantly reduced in sera from patients with MASLD, particularly in those with simple steatosis. Both microRNAs effectively distinguished MASLD patients with simple steatosis from healthy controls (area under the curve: 0.95 and 0.89, respectively). Moreover, miR-4651 emerged as the best predictor for differentiating "complicated" MASLD (i.e., MASH or cirrhosis) from simple steatosis; the predictive values could be increased by including additional parameters into the models (Fibroscan, thrombocytes, cytokines, or other miRNAs). miR-335-5p showed strong ability to differentiate HCC from healthy individuals (area under the curve: 0.86). The p.I148M genotype was not associated with altered levels of microRNAs.
[CONCLUSION] Serum microRNAs, in particular miR-4651, may serve as additional biomarkers in patients with steatotic liver disease.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.